Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service.
It is now possible to use a positive control (Roflumilast) in a drug efficacy evaluation study using porcine pancreatic elastase (PPE)-induced COPD model.
The drug used as a positive control is roflumilast, a PDE-4 inhibitor.
Mean linear intercept by histological analysis of the lungs, the primary endpoint of the COPD model, was significantly lower in the roflumilast-treated group compared with the vehicle group, confirming the protective effect of roflumilast on lung alveolar wall destruction. As the action of roflumilast has been shown to be reproducible, we have established roflumilast as a positive control in our study with the COPD model.
The significance of a positive control in a drug efficacy evaluation study is to demonstrate the efficacy of the test substance to the same degree as a known effective treatment and to demonstrate the efficacy of the test treatment by showing the superiority of the test treatment in direct comparison with the positive control. In other words, by establishing a positive control, the drug efficacy of the test substance can be evaluated by comparing it to the positive control.
Why not use this positive control to carry out a drug efficacy evaluation study of your test substance?
If you have any questions or requests for more information, please feel free to contact us.